Table 3.
Incidence of AEs
Treatment-related AEs, n (%) | Osimertinib group (n = 40) |
Osimertinib + RT group (n = 21) |
P |
---|---|---|---|
Any grade | 13 (32.5) | 10 (47.6) | 0.762 |
Fatigue | 1 (2.5) | 0 (0) | |
Rash | 5 (12.5) | 1 (4.7) | |
Diarrhea | 3 (7.5) | 1 (4.7) | |
Myocardial damage | 2 (5.0) | 0 (0) | |
Pneumonitis | 3 (7.5) | 0 (0) | |
Oral ulcer | 0 (0) | 1 (4.7) | |
Leukoencephalopathy | 0 (0) | 6 (28.5) | |
Neutrophil count decreased | 6 (15.0) | 3 (14.2) | |
Grade ≥ 3 | 3 (7.5) | 4 (19.0) | 0.220 |
Neutrophil count decreased | 3 (7.5) | 1 (4.7) | |
Leukoencephalopathy | 0 | 3 (14.2) |
RT cranial radiotherapy